AxoGen

AxoGen Debt

The Debt of AxoGen (AXGN) as of Sep 27, 2026 is 48.44 M USD. In the previous year, Debt was 47.54 M USD — a change of 1.90% (higher).

Debt

48.44 MUSD

YoY

1.90%

Last updated:

In 2026, AxoGen's total debt was 48.44 M USD, a 1.90% change from the 47.54 M USD total debt recorded in the previous year.

The AxoGen Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
100,000.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
32.10 M USD
Jan 1, 2021
44.80 M USD
Jan 1, 2022
45.70 M USD
Jan 1, 2023
46.63 M USD
Jan 1, 2024
47.54 M USD
Jan 1, 2025
48.44 M USD
The AxoGen Debt history
YEARDebtYoY
48.44 MUSD+1.90%
47.54 MUSD+1.95%
46.63 MUSD+2.03%
45.70 MUSD+2.01%
44.80 MUSD+39.56%
32.10 MUSD—
0.00USD-100.00%
100,000.00USD-99.59%
24.50 MUSD+0.82%
24.30 MUSD-1.62%
24.70 MUSD-1.59%
25.10 MUSD—
Access this data via the Eulerpool API

AxoGen Stock analysis

What does AxoGen do? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen is one of the most popular companies on Eulerpool.

Debt Details

Understanding AxoGen's Debt Structure

AxoGen's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing AxoGen's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to AxoGen’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in AxoGen’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about AxoGen stock

Debt of AxoGen is 48.44 M USD in 2026.

Debt of AxoGen changed from 47.54 M USD to 48.44 M USD, representing a 1.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt AxoGen since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's AxoGen historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — AxoGen

All Key Metrics — AxoGen